Tanox, Inc. Initiates Phase 1 Clinical Trial Evaluating TNX-650 For Treatment Of Asthma

October 25, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

HOUSTON, Oct. 25 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX - News) has begun dosing a Phase 1 clinical trial of TNX-650, a humanized monoclonal antibody being evaluated as a potential treatment for moderate-to-severe asthma.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase I